Category Archives: Meetings

Who's the More Innovative: CROs or Pharma?

CROs and pharma battled for the innovation crown at last week’s annual PCMG’s conference. Julian Upton reports. It’s rather refreshing, in these gloomy economic times, to attend an event that bucks the trend for austerity, and the Pharmaceutical Contract Management Group (PCMG) annual conference last week certainly did that. For the last four years of its [...]
Also posted in Global, R&D | Tagged , , , , , , | 3 Comments

Fixing Innovation: Lilly's CEO Says Why, and How

Following his keynote address last week at the Financial Times US Healthcare and Life Sciences Conference in New York, Eli Lilly CEO John Lechleiter huddled into a corridor to speak with PharmExec about his agenda as incoming chairman of PhRMA, and how to fix innovation.
Also posted in Europe, Events, FDA, Global, IP, Legal, Market Access, People, R&D, Regulatory, Safety, Strategy, Technology, healthcare, leadership, pricing | Tagged , , , , , , , , , , , , , | 1 Comment

The Rising Clout of the Patient

by Sarah Krüg In 2011, the patient’s clout as a stakeholder was firmly established, as reflected in several industry conferences. What’s next for the patient in 2012?
Also posted in Events, Patient Communication, Strategy, Technology, leadership, patient education, social media | Tagged , , | 1 Comment

The Rise of the Patient: Medicine 2.0

by Sarah Krüg Amidst yellow sandstone arches and California Mission Revival architecture, The Medicine 2.0 +Stanford Summit (otherwise known as the Fourth World Congress on Social Media and Web 2.0 in Health Medicine) set out on a three day journey to challenge its diverse audience to break down silos and expand beyond traditional boundaries. From a [...]
Also posted in Patient Communication, Strategy, Technology, healthcare, leadership, patient compliance, patient education, social media | Tagged , | Leave a comment

DIA: Social Media Guidelines are DDMAC’s "Highest Priority"

Tom Abrams, director of FDA’s Division (soon to be Office) of Drug Marketing, Advertising & Communications (DDMAC), said that publishing social media guidelines for industry is the division’s “highest priority,” and that the document will be “published as soon as it’s vetted.”
Also posted in Advertising, E-Media, FDA, Marketing, Regulatory, Strategy, Technology, patient education, social media | Tagged , , | 1 Comment